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ll ligands of the epidermal growth factor receptor
(EGFR), which has important roles in development
and disease, are released from the membrane by
proteases. In several instances, ectodomain release is critical
for activation of EGFR ligands, highlighting the importance
of identifying EGFR ligand sheddases. Here, we uncovered
the sheddases for six EGFR ligands using mouse embryonic
cells lacking candidate-releasing enzymes (a disintegrin
and metalloprotease [ADAM] 9, 10, 12, 15, 17, and 19).
ADAM10 emerged as the main sheddase of EGF and be-
tacellulin, and ADAM17 as the major convertase of epireg-
A
 
ulin, transforming growth factor 
 
 
 
, amphiregulin, and
heparin-binding EGF-like growth factor in these cells.
Analysis of 
 
adam9/12/15/17
 
 
 
/
 
 
 
 knockout mice corroborated
the essential role of 
 
adam17
 
 
 
/
 
 
 
 in activating the EGFR in
vivo. This comprehensive evaluation of EGFR ligand shed-
ding in a deﬁned experimental system demonstrates that
ADAMs have critical roles in releasing all EGFR ligands
tested here. Identiﬁcation of EGFR ligand sheddases is a
crucial step toward understanding the mechanism underlying
ectodomain release, and has implications for designing novel
inhibitors of EGFR-dependent tumors.
 
Introduction
 
The epidermal growth factor receptor (EGFR) signaling
pathway has critical functions in development and in diseases
such as cancer (Yarden and Sliwkowski, 2001). Ligands of
the EGFR comprise a family of structurally and functionally
related integral membrane proteins that can be proteolytically
processed and released from cells (Harris et al., 2003).
EGFR ligands include EGF (Cohen, 1965), heparin-binding
EGF-like growth factor (HB-EGF; Higashiyama et al.,
1991), TGF
 
 
 
 (Derynck et al., 1984), betacellulin (Shing et
al., 1993), amphiregulin (Shoyab et al., 1989), epiregulin
(Toyoda et al., 1995), and epigen (Strachan et al., 2001).
Although membrane-bound EGFR ligands can engage in
juxtacrine signaling (Brachmann et al., 1989; Wong et al.,
1989; Higashiyama et al., 1991), a metalloprotease activity
is critical for activation of EGFR signaling under a variety of
circumstances. For example, EGFR-dependent proliferation
and migration of a mammary epithelial cell line can be inhib-
ited by the metalloprotease inhibitor batimastat (BB94), and
this inhibition is rescued by addition of soluble EGF (Dong
et al., 1999). Furthermore, activation of TGF
 
 
 
 and potentially
other EGFR ligands during mouse development depends on
the presence of functional ADAM17 (Peschon et al., 1998).
Moreover, the metalloprotease-dependent release of HB-EGF
as well as amphiregulin from cells has been described as a
key step in the transactivation of the EGFR by different G
protein–coupled receptors (GPCRs; Prenzel et al., 1999;
Gschwind et al., 2003; Lemjabbar et al., 2003). Production
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of soluble HB-EGF by keratinocytes is up-regulated in re-
sponse to wounding, and a metalloprotease inhibitor that
blocks release of EGFR ligands from these cells abolishes
their migration in vitro, and wound healing in vivo (Toku-
maru et al., 2000). Shedding of HB-EGF also has an im-
portant role in heart development (Jackson et al., 2003;
Yamazaki et al., 2003) and in a mouse model of myocardial
hypertrophy, which can be prevented through a metallopro-
tease inhibitor (Asakura et al., 2002). A recent report dem-
onstrates that even juxtacrine activation of the EGFR by
TGF
 
 
 
 on an adjacent cell can require a metalloprotease ac-
tivity (Borrell-Pages et al., 2003). Finally, all three EGFR
ligands in 
 
Drosophila
 
 (Spitz, Gurken, and Keren) are acti-
vated via cleavage of their transmembrane anchors (Lee et
al., 2001; Urban et al., 2001; Ghiglione et al., 2002; Tsruya
et al., 2002; Shilo, 2003). However, in 
 
Drosophila
 
, different
proteolytic enzymes, the Rhomboid-type proteases, have
been implicated in this process (Urban et al., 2002). Thus,
proteolytic processing of EGFR ligands is emerging as a crit-
ical step in their functional regulation under several different
circumstances.
Metalloproteases of the ADAM (a disintegrin and metallo-
protease) family are thought to be responsible for shedding of
certain EGFR ligands. ADAMs are membrane-anchored gly-
coproteins with diverse functions, including critical roles in
fertilization, neurogenesis, angiogenesis, and in shedding of
membrane-bound proteins from cells (Black and White,
1998; Schlöndorff and Blobel, 1999; Primakoff and Myles,
2000; Seals and Courtneidge, 2003). Mice lacking ADAM17
die perinatally and resemble mice lacking TGF
 
 
 
 (Mann et
al., 1993), HB-EGF (Iwamoto et al., 2003; Jackson et al.,
2003), and the EGFR (Miettinen et al., 1995; Sibilia and
Wagner, 1995; Threadgill et al., 1995; Peschon et al., 1998).
Consistent with these observations, ADAM17-deficient cells
have been shown to be defective in shedding of TGF
 
 
 
, HB-
EGF, and amphiregulin (Peschon et al., 1998; Merlos-Suarez
et al., 2001; Sunnarborg et al., 2002). However, in addition
to ADAM17, three other ADAMs have been linked to HB-
EGF shedding. Overexpression of ADAM9 increases HB-
EGF shedding in VeroH cells, whereas a mutant form of
ADAM9 that is presumably unfolded and retained in the ER
decreases HB-EGF shedding (Izumi et al., 1998); yet no
defect in HB-EGF shedding was observed in cells lacking
ADAM9 (Weskamp et al., 2002). Furthermore, ADAM12
reportedly has a role in HB-EGF shedding in the heart
(Asakura et al., 2002) and in the down-regulation of cell-asso-
ciated HB-EGF after stimulation with the phorbol ester PMA
(Kurisaki et al., 2003). ADAM10 is the fourth ADAM to be
implicated in HB-EGF shedding as part of the crosstalk be-
tween GPCRs and the EGFR (Lemjabbar and Basbaum,
2002; Yan et al., 2002). The remaining EGFR ligands, EGF,
betacellulin, epiregulin, and epigen, are also known to be shed
from cells, yet little information is available about the respon-
sible enzyme(s) (Dempsey et al., 1997; Harris et al., 2003).
A crucial step toward understanding the mechanism un-
derlying proteolytic cleavage of EGFR ligands (and its poten-
tial role in their activation) is to identify the responsible en-
zyme(s). In previous papers, different cell types and different
approaches were used to analyze shedding of some EGFR
ligands (see previous paragraphs), including antisense oligo-
nucleotides and overexpression of both wild-type and puta-
tive dominant-negative ADAM constructs. Here, we chose a
genetically defined system that is less prone to potential arti-
facts to evaluate the role of ADAMs in EGFR ligand shed-
ding. To address potential compensatory or redundant func-
tions between ADAMs 9, 12, 15, and 17, we generated
 
adam9/12/15
 
 
 
/
 
 
 
 and 
 
adam9/12/15/17
 
 
 
/
 
 
 
 mice. Furthermore,
we used cells isolated from wild-type, 
 
adam9/12/15
 
 
 
/
 
 
 
,
 
adam10
 
 
 
/
 
 
 
, adam17
 
 
 
/
 
 
 
, adam19
 
 
 
/
 
 
 
,
 
 or 
 
adam9/12/15/17
 
 
 
/
 
 
 
mice to evaluate how loss of one or more widely expressed
ADAMs affects the shedding of different EGFR ligands. This
paper represents the first systematic characterization of EGFR
ligand processing using mouse cells that lack one or more
candidate sheddase of the ADAM family of metalloproteases.
 
Results
 
Generation of 
 
adam9/12/15
 
 
 
/
 
 
 
 triple knockout 
mice to assess potential compensatory or redundant 
roles of these candidate EGFR ligand sheddases in 
mouse development
 
ADAMs 9 and 12 have previously been implicated as shed-
dases for HB-EGF (Izumi et al., 1998; Asakura et al., 2002;
Kurisaki et al., 2003). To evaluate potential redundant or
compensatory roles of ADAMs 9 and 12, as well as the re-
lated ADAM 15 in development and in the shedding of HB-
EGF and other EGFR ligands, we generated double knock-
out mice (
 
adam9/15
 
 
 
/
 
 
 
) and triple knockout mice (
 
adam9/
12/15
 
 
 
/
 
 
 
) as described in the Materials and methods. Table
I shows that 
 
adam9/15
 
 
 
/
 
 
 
 double knockout mice were born
with the expected Mendelian ratio from matings of doubly
heterozygous parents. 
 
adam9/15
 
 
 
/
 
 
 
 mice were viable and
fertile, and did not display any evident spontaneous patho-
logical phenotypes (see Materials and methods for details).
 
Table I. 
 
Genotype of offspring from matings of
 
adam9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
 parents
Genotype of offspring Expected Observed
 
%%
 
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
6.25 5.5 (10)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12.5 15.0 (27)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
6.25 5.0 (9)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12.5 12.8 (23)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
25.0 23.9 (43)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12.5 12.8 (23)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
6.25 5.5 (10)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12.5 15.5 (27)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
6.25 4.4 (8)
Numbers in parentheses, # (total of 180).
Table II. 
 
Genotype of offspring from matings of
 
adam9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12
 
 
 
/
 
 
 
 parents
Genotype of offspring Percent
 
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12
 
 
 
/
 
 
 
30.1 (50)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12
 
 
 
/
 
 
 
44.0 (73)
9
 
 
 
/
 
 
 
15
 
 
 
/
 
 
 
12
 
 
 
/
 
 
 
25.9 (43)
Numbers in parentheses, # (total of 166). 
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Triple knockout mice lacking ADAMs 9, 12, and 15 were
generated by mating 
 
adam9/15
 
 
 
/
 
 
 
 parents carrying one mu-
tant ADAM12 allele (
 
adam9/15
 
 
 
/
 
 
 
12
 
 
 
/
 
 
 
). The genotype of
offspring from these matings was Mendelian with respect to
the mutant ADAM12 allele (Table II), and 
 
adam9/12/15
 
 
 
/
 
 
 
triple knockout mice were viable and fertile and did not dis-
play any evident pathological phenotypes (see below, and
Materials and methods for details).
 
Ectodomain shedding of EGFR ligands in mouse 
embryonic fibroblasts
 
To further explore the role of ADAMs in EGFR ligand shed-
ding, we turned to cell-based assays using cells isolated from
triple knockout 
 
adam9/12/15
 
 
 
/
 
 
 
 mice, as well as from ani-
mals lacking ADAM10, ADAM17, or ADAM19, and wild-
type controls. This allowed us to evaluate the contribution of
all but one of the widely expressed and catalytically active
ADAMs (ADAMs 9, 10, 12, 15, 17, and 19; see Fig. 1;
ADAM33 was not included in this work) to the shedding of
the EGFR ligands TGF
 
 
 
, amphiregulin, epiregulin, HB-
EGF, betacellulin, and EGF. The general approach was to
transfect cells with alkaline phosphatase (AP)–tagged forms
of EGFR ligands, and then to quantitate shedding by mea-
suring AP activity released into the culture supernatant, or by
an in-gel detection of the released AP domain (Weskamp et
al., 2002; Zheng et al., 2002; see Materials and methods for
details). Because immortalization of primary cells can signifi-
cantly affect the expression pattern of ADAMs and other
genes (unpublished data), shedding experiments were per-
formed with primary E13.5 mouse embryonic fibroblasts
(MEFs) whenever this was possible. The only exceptions
were 
 
adam10
 
 
 
/
 
 
 
 and 
 
adam10
 
 
 
/
 
 
 
 cell lines, which were im-
mortalized because adam10
 /  embryos die early in embryo-
genesis (E9.5) (Hartmann et al., 2002). Northern or Western
blot analyses confirmed that primary mEFs from wild-type
mice indeed express all ADAMs analyzed here (ADAMs9,
10, 12, 15, 17, and 19; see Fig. 1). Furthermore, Northern
blots of RNA isolated from primary adam
 /  cells confirmed
the absence of wild-type RNA for the corresponding targeted
ADAM(s). Finally, Western blot analysis confirmed that
ADAM10 is expressed in all adam
 /  primary mEFs, and
that no mature ADAM17 is produced in adam17
 /  cells.
As differences in expression levels between tissue culture
wells or separate experiments might affect the interpretation
of these experiments, each data point was derived from two
consecutive measurements of AP activity shed from a single
transfected well (see Fig. 2 A). Stimulation of EGFR ligand
shedding in a given well was determined by collecting me-
dium after 1 h from unstimulated cells, and then after 1 h
from the same cells stimulated with the phorbol ester PMA, a
Figure 1. Expression of widely expressed and catalytically active ADAMs in MEFs. ADAMs are grouped by expression pattern and presence 
or absence of a catalytic site (HEXXH) in the metalloprotease domain. 27 ADAMs have been identified in mice, of which 10 lack an HEXXH 
sequence, and are presumably not catalytically active. Out of 17 ADAMs with an HEXXH sequence, 10 are mainly expressed in the testes or 
epididymis, or are not widely expressed (J.M. White, University of Virginia, Charlottesville, VA; http://www.people.virginia.edu/%7Ejw7g/
Table_of_the_ADAMs.html). Six of the seven widely expressed HEXXH-containing ADAMs were included in this paper. The top right panel 
shows a Northern blot analysis of the expression of ADAMs 9, 12, 15, and 19 in primary MEFs. The ADAM19 mRNA in adam19
 /  cells is 
larger than in the other cells analyzed because the ADAM19 gene is disrupted by insertion of a secretory gene trap (Zhou et al., 2004). The 
bottom right panel is a Western blot depicting expression of ADAMs 10 and 17 in the primary embryonic fibroblasts used here. Both pro- and 
mature ADAM10 are expressed in all primary mEFs analyzed here, and pro- and mature ADAM17 are expressed in wild-type, adam19
 / , and 
adam9/12/15
 /  cells. Note that the exon containing the Zn
2 -binding catalytic site of ADAM17 is deleted in adam17
 /  cells (ADAM17
 Zn/ Zn). 
This will most likely impair proper protein folding, resulting in retention of mutant ADAM17 in the ER by chaperones and subsequent degra-
dation (Suzuki et al., 1998). wt, wild type; 17
 / , adam17
 / ; 19
 / , adam19
 / ; T
 / , adam9/12/15
 /  triple knockout; P, pro-form; M, mature.772 The Journal of Cell Biology | Volume 164, Number 5, 2004
commonly used activator of ectodomain shedding (Massague
and Pandiella, 1993; Hooper et al., 1997; see Fig. 3 A). This
was used to calculate the increase in shedding in a given well
during PMA stimulation. The batimastat-sensitive constitu-
tive shedding was determined similarly, by measuring the de-
crease in AP activity in media collected after 1 h in the pres-
ence of batimastat and comparing it to the AP activity
released from the same well collected 1 h before treatment
(see Fig. 4 A). This single-well assay minimizes possible ef-
fects caused by different transfection levels. Nevertheless, the
absolute values for constitutive shedding from different wild-
type or primary adam
 /  cells expressing a given EGFR
ligand were also determined to provide a reference point for
the comparison of total unstimulated shedding levels.
Shedding of EGFR ligands in wild-type cells
Shedding of EGFR ligands was first evaluated in wild-type
MEFs. As shown in Fig. 2 B, unstimulated mEFs shed basal
amounts of TGF , amphiregulin, epiregulin, HB-EGF, be-
tacellulin, and EGF. In the case of TGF , amphiregulin, epi-
regulin, and HB-EGF, shedding was stimulated relatively
strongly by PMA, whereas shedding of betacellulin and EGF
was only weakly enhanced by PMA (see also Fig. 3 A). Treat-
ment with the metalloprotease inhibitor batimastat strongly
reduced both PMA-stimulated (unpublished data) and con-
stitutive shedding of all EGF family members except HB-
EGF. Although stimulated HB-EGF shedding was effectively
inhibited by batimastat (unpublished data), constitutive re-
lease was only weakly affected (see also Fig. 4 A), suggesting
that the predominant constitutive HB-EGF sheddase in pri-
mary mEFs is not a batimastat-sensitive metalloprotease, and
is distinct from the sheddase(s) of other EGFR ligands.
PMA-stimulated shedding of EGFR ligands 
in adam
 /  cells
The potential role of different ADAMs as EGFR ligand shed-
dases was then addressed in adam
 /  mEFs. When we evalu-
ated PMA-stimulated EGFR ligand shedding in triple knock-
out adam9/12/15
 /  cells, no significant decrease in the release
of HB-EGF, TGF , amphiregulin, EGF, or betacellulin com-
pared with wild-type cells was observed (Fig. 3 A). However,
there was a statistically significant reduction in stimulated
shedding of epiregulin in adam9/12/15
 /  cells (41.8%), sug-
gesting that one or more of these ADAMs contributes to stim-
ulated epiregulin processing. Similarly, we found no evidence
for a major role of ADAM19 in stimulated shedding of the
EGFR ligands tested here (Fig. 3 A). The reason for the slight
increase in HB-EGF shedding in adam19
 /  cells compared
with wild-type controls remains to be determined.
ADAM17 has been implicated in the shedding of TGF 
and HB-EGF in immortalized embryonic fibroblasts and
primary keratinocytes (Peschon et al., 1998; Merlos-Suarez
et al., 2001; Sunnarborg et al., 2002), and of amphiregulin
in primary keratinocytes (Sunnarborg et al., 2002). Consis-
tent with these results, we observed a significant reduction of
PMA-induced shedding of TGF  (89%), amphiregulin
(65.8%), and HB-EGF (58.1%) in adam17
 /  compared
with wild-type mEFs (Fig. 3 A). Furthermore, shedding of
epiregulin was also strongly decreased in adam17
 /  cells
(75.7%), providing the first evidence for a critical role of
ADAM17 in stimulated shedding of this EGFR ligand.
For TGF , amphiregulin, and epiregulin, PMA-dependent
ectodomain shedding in adam17
 /  cells was increased
when wild-type ADAM17 was cotransfected, confirming
that the defect in PMA-dependent shedding is indeed due to
loss of ADAM17 (unpublished data).
ADAM10 has been implicated in shedding of HB-EGF as
part of a pathway for crosstalk between a GPCR and the
EGFR (Lemjabbar and Basbaum, 2002; Yan et al., 2002).
As shown in Fig. 3, PMA-stimulated shedding of HB-EGF,
TGF , amphiregulin, and epiregulin is not decreased in
adam10
 /  cells, suggesting that ADAM10 is not required
for the PMA-stimulated shedding of these EGFR ligands.
The enhanced stimulated shedding of these EGFR ligands
Figure 2. Shedding of EGFR ligands in wild-type primary MEFs. (A) Diagram of a typical shedding experiment (see text for details). (B) 
Detection of shed AP-tagged EGFR ligands after renaturation in SDS gels (see Materials and methods for details). The left lane shows the 
AP-tagged forms of TGF , amphiregulin, epiregulin, HB-EGF, betacellulin, and EGF released in 1 h into the supernatant of a single well each 
of transfected mEF under resting conditions. The next lane shows the EGFR ligands released in 1 h from the same well after addition of PMA, 
a phorbol ester that stimulates ectodomain shedding. The third lane shows EGFR ligands released from a separate well in 1 h under resting 
conditions, and the fourth lane shows the released EGFR ligands in that same well after addition of the hydroxamate-based metalloprotease 
inhibitor batimastat (BB94).Role of ADAMs in EGFR ligand shedding | Sahin et al. 773
in adam10
 /  (Fig. 3 A) and adam10
 /  cells (unpublished
data) compared with the primary mEFs is presumably a con-
sequence of immortalization.
Generation of adam9/12/15/17
 /  quadruple knockout 
mice, and evaluation of PMA-stimulated EGFR ligand 
shedding in adam9/12/15/17
 /  cells
Although ADAM17 is essential for the majority of stimu-
lated shedding of HB-EGF in mEF cells, a residual amount
of PMA-stimulated HB-EGF shedding is seen in the absence
of ADAM17. Could this residual shedding depend on
ADAMs 9 or 12, both of which have been implicated in
HB-EGF shedding, or on the related ADAM15? To address
this issue, we generated quadruple knockout mice lacking
ADAMs 9, 12, 15, and 17 (see Materials and methods for
details). Similar to adam17
 /  mice, adam9/12/15/17
 /  qua-
druple knockout mice that were born had open eyes and
died in the first day after birth. The percentage of adam9/12/
15/17
 /  quadruple knockout embryos at E18.5 generated
by mating adam9
 / 12
 / 15
 / 17
 /  parents was some-
what lower than the percentage of adam17
 /  embryos at
E17.5–18.5 produced by mating adam17
 /  mice (Table
III; Peschon et al., 1998).
To determine whether the loss of ADAMs 9, 12, and 15 ex-
acerbates known defects in EGFR signaling in adam17
 / 
mice, we performed a histopathological examination of wild-
type, adam9/12/15
 / , adam17
 / , and adam9/12/15/17
 / 
E18.5 embryos. As shown in Fig. 3 B (panels A–D), the open-
eye phenotype in adam17
 /  mice that results from lack of
TGF  activation (Peschon et al., 1998) is similar in adam9/
Figure 3.  PMA-stimulated shedding of EGFR ligands in adam
 /  cells. (A) The 
first panel shows an explanatory diagram depicting how increases in ectodomain 
shedding of different EGFR ligands from a given well are presented in the 
remaining panels of this figure. Shedding stimulated by 20 ng/ml PMA for 1 h 
is calculated as the percent increase in AP activity over constitutive shedding 
in the same well for 1 h. The next panels only show the PMA-dependent increase in shedding over constitutive levels for each EGFR ligand 
and each adam
 /  cell type. Data from primary mEFs (yellow bars) are compiled from separate experiments using cells from three or more 
litters for each adam
 /  mouse line. Only adam10
 /  and control adam10
 /  cells were immortalized (blue bars). Overall, at least four separate 
wells were evaluated per EGFR ligand. The results indicate that ADAM17 is the major stimulated sheddase for TGF , amphiregulin, epiregulin, 
and HB-EGF. ADAMs 9, 12, or 15 (or a combination of two or more of these ADAMs) also contribute to stimulated epiregulin shedding. On 
the other hand, the shedding of betacellulin and EGF is only weakly stimulated by PMA. Because the increase in stimulated shedding is small, 
no statistically significant differences in stimulated shedding of betacellulin or EGF was seen in adam
 /  cells compared with wild-type controls. 
(B) Histological analysis of sectioned hematoxylin and eosin–stained eyes and eyelids (A–D), aortic valves (E–H), pulmonic valves (I–L), and 
tricuspid valves (M–P) of newborn wild-type (A, E, I, and M), adam9/12/15
 /  (B, F, J, and N), adam17
 /  (C, G, K, and O), and adam9/12/
15/17
 /  (D, H, L, and P) mice. Eyelids of wild-type and adam9/12/15
 /  mice are closed at birth (A and B), whereas those of adam17
 /  and 
adam9/12/15/17
 /  mice are open (C and D). The aortic, pulmonic, and tricuspid valves of adam9/12/15
 /  mice (F, J, and N) resemble those 
of wild-type mice (E, I, and M, respectively), whereas these valves are thickened and misshapen in adam17
 /  (G, K, and C) and adam9/12/
15/17
 /  quadruple knockout mice (H, L, and P). The valve defects in adam9/12/15/17
 /  quadruple knockout mice, which also include 
thickened and misshapen mitral valves (not depicted), are comparable to those in adam17
 /  mice. Eyelids in A–D marked by red arrows, 
heart valves in E–P marked by yellow arrows. Bar (E–P), 100  m.774 The Journal of Cell Biology | Volume 164, Number 5, 2004
12/15/17
 /  quadruple knockout mice, whereas it is not seen
in adam9/12/15
 /  triple knockout mice. Furthermore, Jack-
son et al. (2003) have described a defect in morphogenesis of
the semilunar heart valves and the tricuspid and mitral valves
in adam17
 /  mice (Fig. 3 B, panels E–P; mitral valve not de-
picted), which resembles the thickened and misshapen valves
seen in hb-egf
 /  mice and in mice with a knock-in mutation
that abolishes HB-EGF shedding (Iwamoto et al., 2003;
Yamazaki et al., 2003). As shown in Fig. 3 B, the heart valves
in adam9/12/15
 /  triple knockout mice are indistinguishable
from those in wild-type mice, and again, the defects in heart
valve morphogenesis in adam17
 /  mice are comparable to
the defects in adam9/12/15/17
 /  quadruple knockout mice.
A morphometric analysis of all heart valves of six adam9/12/
15/17
 /  E18.5 embryos also did not show an increased size
Table III. Offspring of matings of adam9/12/15
 / 17
 /  parents
Genotype of E18.5 embryos Percent
9
 / 15
 / 12
 / 17
 /  36.7 (36)
9
 / 15
 / 12
 / 17
 /  49.0 (48)
9
 / 15
 / 12
 / 17
 /  14.3 (14) [4]
Genotype of E17.5–18.5 embryos
17
 /  23.3 (23)
17
 /  57.3 (59)
17
 /  20.4 (21) [4]
Genotype of E18.5 embryos from matings of adam9
 / 15
 / 12
 / 17
 / 
parents. Numbers in parentheses, # (total of 98). Genotype of E17.5–18.5
embryos from matings of adam17
 /  parents, taken from Peschon et al.
(1998). Numbers in parentheses, # (total of 103). Nonviable embryos are
indicated in brackets.
Figure 4. Batimastat-sensitive constitutive shedding of EGFR ligands in adam
 /  cells. (A) A diagram indicating how the batimastat-sensitive 
component of ectodomain shedding of different EGFR ligands from a given well of resting cells was determined. Shedding of EGFR ligands in 
1 h from resting cells is used as a reference to determine the percentage of batimastat-sensitive constitutive shedding (percent decrease after 
addition of batimastat). The next panels show the batimastat-sensitive decrease in shedding of each EGFR ligand in each adam
 /  cell type. 
As in Fig. 3, separate experiments were performed with cells from three or more litters for each adam
 /  mouse line. At least six separate wells 
were analyzed for adam10
 /  and control adam10
 /  cells, which were immortalized (blue bars). Several wells were evaluated in each 
experiment for each lot of cells and for each EGFR ligand. The results show that ADAMs 9, 10, 12, 15, and 19 are not essential for the batimastat-Role of ADAMs in EGFR ligand shedding | Sahin et al. 775
compared with six adam17
 /  E18.5 embryos (unpublished
data). When we performed shedding experiments with
adam9/12/15/17
 /  quadruple knockout mEFs, the residual
amount of PMA-stimulated HB-EGF shedding was compara-
ble to what is observed in adam17
 /  cells (percent increase in
HB-EGF shedding after PMA stimulation in adam9/12/15/
17
 /  mEF: 33.3   26.5%, n   16; four embryos, 2–6 wells
analyzed per embryo); compared with 33.7   12.9% in
adam17
 /  mEF; Fig. 3 A). Together, these results argue
against a significant contribution of ADAMs 9, 12, or 15 to
the shedding of HB-EGF in these cells.
Constitutive shedding of EGFR ligands in adam
 /  cells
Next, we evaluated the batimastat-sensitive component of
constitutive shedding of EGFR ligands in the presence or ab-
sence of different ADAMs. No significant difference in the
batimastat-sensitive constitutive shedding of all six ligands
tested here was observed in adam9/12/15
 /  or adam19
 / 
cells compared with wild-type controls (Fig. 4 A). Further-
more, constitutive shedding of TGF , amphiregulin, epiregu-
lin, and HB-EGF was also not affected in adam10
 /  cells.
Because the shedding assay used here relies on measure-
ments of the percent increase (see above) or decrease in shed-
ding after treatment compared with unstimulated shedding, it
is important to ensure that the levels of unstimulated shed-
ding are indeed similar in different adam
 /  and wild-type
cells. In experiments where wild-type cells were evaluated si-
multaneously with adam9/12/15
 /  or adam19
 /  cells, com-
parable amounts of each EGFR ligand analyzed here were re-
leased from unstimulated cells (unpublished data). However,
the overall levels of constitutive shedding for TGF , amphi-
regulin, epiregulin, and HB-EGF (but not EGF and betacel-
lulin) were reduced in adam17
 /  cells compared with wild-
type controls (Fig. 4 A, insets; unpublished data). This dem-
onstrates that ADAM17 has a key role in both stimulated and
constitutive shedding of these EGFR ligands.
Interestingly, when we measured the batimastat-sensitive
constitutive shedding of EGF and betacellulin, we found that
it was abrogated in two independent adam10
 /  cell lines
compared with control adam10
 /  cells and the primary
mEF cells (Fig. 4 A; unpublished data). This resulted in a
strong decrease in overall unstimulated constitutive shedding
of betacellulin (87.5%) and EGF (49.7%) from adam10
 / 
cells compared with adam10
 /  cells (unpublished data).
Constitutive shedding of betacellulin and EGF could be res-
cued with wild-type ADAM10, confirming that the defect
in shedding in adam10
 /  cells is indeed due to the lack
of ADAM10 (Fig. 4 B). Next, we evaluated the role of
ADAM10 in betacellulin-dependent EGFR signaling in
adam10
 /  cells. When either ADAM10 or betacellulin were
introduced in adam10
 /  cells, there was no increase in phos-
phorylation of ERK1/2, a commonly used indicator for acti-
vation of the EGFR (Fig. 4 C). However, when wild-type
ADAM10 was cotransfected with betacellulin in adam10
 / 
cells, ERK1/2 phosphorylation was increased (Fig. 4 C).
Thus, EGFR signaling via transfected betacellulin depends
on the presence of functional ADAM10 in these cells. To-
gether, these results are the first to identify the major shed-
dase for EGF and betacellulin in mouse embryonic cells, and
thus also to uncover two novel substrates for ADAM10.
To address whether the results obtained in mEF cells
could in principle also be relevant for other cells and tissues,
Western blot analysis of the expression of ADAMs 10 and
17 in different mouse tissues was performed (Fig. 5). This
sensitive constitutive shedding of TGF , amphiregulin, epiregulin, and HB-EGF. The absolute levels of constitutive release of each EGFR ligand 
were comparable between wild-type, adam9/12/15
 / , and adam19
 /  cells (not depicted). However, the levels of constitutive shedding of 
TGF , amphiregulin, epiregulin, and HB-EGF were significantly reduced in adam17
 /  cells compared with wild-type controls (see inset gel 
figures; SN, supernatant; CL, cell lysate), indicating that ADAM17 is also the major constitutive sheddase for these ligands. Data on the 
batimastat-sensitive shedding in adam17
 /  cells are not included in the graph because addition of batimastat further decreases the small 
amount of constitutive shedding in adam17
 /  cells. Thus, another metalloprotease besides ADAM17 apparently makes a very minor contri-
bution to shedding of these four substrates. The batimastat-sensitive shedding of betacellulin and EGF was very similar in adam9/12/15
 / , 
adam19
 / , adam17
 / , and adam10
 /  mEFs compared with wild-type controls. Although the absolute levels of constitutive shedding from 
these cells were also very similar (not depicted), constitutive shedding of betacellulin from adam10
 /  cells was decreased by 87.5%, whereas 
shedding of EGF was decreased by 49.7% compared with adam10
 /  cells. In the absence of ADAM10, the remaining small amount of 
constitutive shedding was not inhibitable by batimastat. (B) Batimastat-sensitive shedding of betacellulin (BTC) and EGF from adam10
 /  cells 
can be rescued by cotransfection with wild-type ADAM10 (A10; each bar represents the results from six tissue culture wells). These results 
confirm that the defect in EGF and betacellulin shedding in adam10
 /  cells is indeed due to the absence of ADAM10. (C) Constitutive 
phosphorylation of ERK1/2 in adam10
 /  cells transfected with the pcDNA3 vector (V, lane 1) is not increased by transfection with BTC (lane 2) 
or ADAM10 (lane 3). However, ERK1/2 phosphorylation is increased when BTC and ADAM10 are cotransfected (lane 4), demonstrating that 
ADAM10 is critical for BTC-dependent EGFR signaling in these cells. The bottom panel shows the same blot reprobed with antibodies against 
total ERK1/2 to confirm equal loading in all lanes.
Figure 5. Evaluation of ADAM10 and ADAM17 protein levels in 
different mouse tissues. Western blots of mouse tissue extracts were 
probed with a polyclonal antiserum against ADAM10 (A) or ADAM17 
(B). Equal amounts of Con A–enriched glycoproteins from the following 
tissues were loaded per lane: brain (lane 1), skeletal muscle (lane 2), 
kidney (lane 3), heart (lane 4), lung (lane 5), spleen (lane 6), testis 
(lane 7), and liver (lane 8). The arrow indicates the position of 
ADAM10 in A, and of ADAM17 in B.776 The Journal of Cell Biology | Volume 164, Number 5, 2004
confirmed that both ADAMs are widely expressed, even
though their expression levels vary. Thus, it is likely that
both ADAMs 10 and 17 are expressed in the cells and tissues
in which the ligands analyzed in this paper exert their func-
tion as activators of EGFR signaling.
Discussion
Protein ectodomain shedding of EGFR ligands can be criti-
cal for their functional activation. All EGFR ligands analyzed
in this paper are synthesized as membrane-anchored precur-
sors, and were initially identified as soluble biologically active
growth factors (Cohen, 1962, 1965; de Larco and Todaro,
1978; Todaro et al., 1980; Shoyab et al., 1989; Higashiyama
et al., 1991; Shing et al., 1993; Toyoda et al., 1995). A key
step in elucidating the mechanism underlying the proteolytic
release of EGFR ligands is the identification of the responsi-
ble sheddases. Although ADAM17 has been implicated in
the shedding of TGF , HB-EGF, and amphiregulin (Mer-
los-Suarez et al., 2001; Sunnarborg et al., 2002; Jackson et
al., 2003), no information was previously available about the
identity of the sheddases for epiregulin, EGF, and betacellu-
lin. Furthermore, three other ADAMs (9, 10, and 12) had
been implicated in HB-EGF shedding (Izumi et al., 1998;
Asakura et al., 2002; Lemjabbar and Basbaum, 2002), raising
questions about their individual contributions to HB-EGF
release. To test the hypothesis that the sheddases for epiregu-
lin, EGF, and betacellulin are also ADAMs, and to further
evaluate the contribution of different ADAMs to HB-EGF
shedding, we studied the release of these proteins from cells
lacking one or more members of this family of metallopro-
teases. Moreover, even though ADAM17 has been linked to
the shedding of TGF  and amphiregulin, we included these
EGFR ligands in our paper both to investigate whether other
ADAMs may participate in the shedding of these two pro-
teins and as a positive control to validate the assay used here.
Finally, we determined the effects of targeted deletions of up
to four ADAMs that are candidate sheddases (ADAMs 9, 12,
15, and 17) on mouse development.
Ectodomain shedding experiments using these six major
EGFR ligands in adam
 /  MEFs corroborated previous re-
ports that ADAM17 has a major role in the shedding of
TGF , HB-EGF, and amphiregulin (Peschon et al., 1998;
Merlos-Suarez et al., 2001; Sunnarborg et al., 2002). We
found no evidence for a major contribution of other ADAMs
besides ADAM17 to TGF , HB-EGF, and amphireg-
ulin  shedding in these cells. Furthermore, epiregulin was
identified as a novel ADAM17 substrate. Previous works
have shown that adam17
 /  mice resemble tgf 
 /  mice
(Peschon et al., 1998) in that they have open eyes at birth, as
well as displaying similar vibrissae, hair, and skin defects
(Mann et al., 1993). Furthermore, adam17
 /  mice also re-
semble hb-egf
 /  mice (Iwamoto et al., 2003) in that they
have thickened aortic and pulmonic valves (Jackson et al.,
2003). A similar phenotype is seen in mice with a mutation
in the cleavage site of HB-EGF that abolishes its shedding
(Yamazaki et al., 2003). Finally, the phenotype of adam17
 / 
mice resembles that of egfr
 /  mice (Miettinen et al.,
1995; Sibilia and Wagner, 1995; Threadgill et al., 1995; Pe-
schon et al., 1998). Thus, genetic experiments have substan-
tiated that ADAM17 is also essential for the activation of
EGFR ligands in vivo. It remains to be determined whether
the lack of processing of amphiregulin or epiregulin (or
both) also contributes to the phenotype of adam17
 /  mice.
ADAMs 9, 10, and 12 are also considered candidate HB-
EGF sheddases (Izumi et al., 1998; Asakura et al., 2002;
Kurisaki et al., 2003). However, although PMA-stimulated
ectodomain shedding of HB-EGF was somewhat reduced in
adam9/12/15
 /  cells, this reduction was not statistically sig-
nificant. In addition, the residual PMA stimulation of HB-
EGF shedding in adam17
 /  cells is most likely also not due
to ADAMs 9, 12, or 15 because it remains unchanged in
adam9/12/15/17
 /  quadruple knockout cells. In a previous
paper, Kurisaki et al. (2003) reported a significant reduction
in the down-regulation of cell-associated HB-EGF in phorbol
ester–stimulated  adam12
 /  cells compared with wild-type
controls. This apparent discrepancy may be due to differences
in cell preparation or experimental design. Nevertheless, the
main conclusion from the side-by-side comparison of differ-
ent adam
 /  cells isolated and cultured under identical condi-
tions in this paper is that ADAM17 is the predominant
PMA-stimulated HB-EGF sheddase in primary mEF cells.
The conclusion that ADAM17 has a critical role in shed-
ding HB-EGF in vivo was further corroborated by an analy-
sis of the role of these ADAMs during mouse development.
As mentioned previously in this paper, adam17
 /  mice re-
semble egfr
 / , tgf 
 / , or hb-egf
 /  mice, whereas no simi-
lar defects were seen in adam9/12/15
 /  mice. Furthermore,
the phenotype of adam17
 /  mice does not appear to be
considerably exacerbated when ADAMs 9, 12, and 15 are
also deleted. Together, these findings argue against major
compensatory or redundant roles for ADAMs 9, 12, and the
related ADAM 15 in the activation of TGF , HB-EGF, or
the EGFR during development. However, it cannot be ruled
out that ADAMs 9, 12, or 15 contribute to shedding of
EGFR ligands in cells or tissues where these enzymes and po-
tential substrates are highly expressed. Further analyses will
address which ADAMs are capable of cleaving EGFR ligands
when overexpressed, and in which tissues candidate EGFR
ligand sheddases besides ADAMs 10 and 17 are highly ex-
pressed together with EGFR ligands that they can cleave.
ADAM10 has also been implicated in HB-EGF shedding
as part of a pathway that involves crosstalk between GPCRs
and the EGFR (Lemjabbar and Basbaum, 2002; Yan et al.,
2002; Lemjabbar et al., 2003). On the other hand, our re-
sults indicate that ADAM10 does not make a major contri-
bution to PMA-stimulated or constitutive shedding of HB-
EGF in the cells tested here. This is consistent with the notion
that different stimuli may activate different ADAMs, such
that HB-EGF shedding depends mainly on ADAM17 under
the conditions used here, and mainly on ADAM10 when
the appropriate GPCR is stimulated.
Little was previously known about the sheddases responsi-
ble for the release of EGF and betacellulin from cells. Here,
we show that constitutive shedding of both EGF and beta-
cellulin was strongly reduced in adam10
 /  cells compared
with heterozygous controls, and could be rescued by reintro-
duction of wild-type ADAM10. Furthermore, stimulation
of the EGFR by transfected betacellulin in adam10
 /  cells
is only seen when these cells are rescued by cotransfectionRole of ADAMs in EGFR ligand shedding | Sahin et al. 777
with wild-type ADAM10. These results are the first to iden-
tify ADAM10 as the major sheddase for these two crucial
EGFR ligands in mouse cells. Because ADAM10 is widely
expressed, it is tempting to speculate that it may participate
in the functional regulation of these two EGFR ligands in
development and in diseases such as cancer.
In light of the genetic evidence for a key role of ADAM17
in activation of EGFR ligands in mice (Peschon et al., 1998;
Sunnarborg et al., 2002; Jackson et al., 2003), it is surprising
that no ADAM has been identified as an essential part of the
EGFR pathway in Drosophila (Lee et al., 2001; Urban et al.,
2001; Ghiglione et al., 2002; Tsruya et al., 2002; Shilo,
2003). Instead, Rhomboids (integral membrane proteins
with seven membrane-spanning domains) have been impli-
cated in cleaving EGFR ligands (Urban et al., 2002), whereas
reducing the expression of a putative ADAM17 orthologue
in Drosophila via small interfering RNA did not block devel-
opment of EGFR-dependent structures (Lee et al., 2001).
These results suggest that there are critical differences in
the mechanism underlying proteolytic activation of EGFR
ligands between flies and mice. However, the finding that all
EGFR ligands tested here are processed by ADAM10 or
ADAM17 in mEFs suggests a possible alternative explana-
tion for these findings. Drosophila carry orthologues of
ADAM10 (KUZ) and ADAM17 (AAF56986, the ADAM
targeted by RNA interference in Lee et al. [2001]), as well as
a third ADAM related to ADAM17 and KUZ with no evi-
dent orthologue in mammals (AAF56926). It is conceivable
that two or three of these ADAMs fulfill redundant or com-
pensatory roles in activation of EGFR ligands during devel-
opment in Drosophila. This may only become apparent once
two or three of these putative EGFR ligand sheddases are si-
multaneously inactivated. Conversely, the results in Dro-
sophila suggest that it will be worthwhile to further investi-
gate the potential role of Rhomboids and intramembrane
proteolysis in EGFR ligand activation in mammals.
In summary, we report the first systematic analysis of the
shedding of EGFR ligands in cells lacking one or more
widely expressed and catalytically active ADAM. Our results
uncover critical roles for both ADAM10 and ADAM17 in
shedding of EGFR ligands in mEF cells. ADAM17 emerged
as the major PMA-stimulated and constitutive sheddase of
TGF , amphiregulin, HB-EGF, and epiregulin, which is
consistent with the essential role for ADAM17 in activation
of the EGFR during development. Furthermore, ADAM10
was found to be the major batimastat-sensitive sheddase for
betacellulin and EGF in mEF. Further experiments, includ-
ing the generation of conditional adam10
 /  knockout
mice, as well as knock-in mutations that abolish shedding of
EGF and betacellulin, will be necessary to address the bio-
logical relevance of ADAM10 in shedding the endogenous
forms of these EGFR ligands in vivo. The identification of
different EGFR ligands as substrates for ADAM10 and
ADAM17 sets the stage for the further analysis of how these
ADAMs are regulated and how their substrate specificity is
achieved. Because proteolysis of EGFR ligands may be criti-
cal for their functional activation, and signaling via the
EGFR has been implicated in diseases such as cancer,
ADAM10 and ADAM17 may be attractive targets for the
design of drugs that modulate the action of these ligands.
Materials and methods
Generation of adam9/15
 / , adam9/12/15
 / , and
adam9/12/15/17
 /  knockout mice
Mice lacking ADAMs 9, 12, or 15 have been described previously
(Weskamp et al., 2002; Horiuchi et al., 2003; Kurisaki et al., 2003). To
generate adam9/15
 /  double knockout mice, we mated adam9
 / 15
 / 
doubly heterozygous parents. This produced offspring in the expected
Mendelian ratio (Table I). adam9/15
 /  double knockout mice were then
mated with adam12
 /  mice (provided by Dr. Fujisawa-Sehara, University
of Kyoto, Kyoto, Japan) to produce adam9
 / 12
 / 15
 /  triple heterozy-
gous parents. These were backcrossed with adam9/15
 /  mice to generate
adam9/15
 / 12
 /  animals. When adam9/15
 / 12
 /  mice were crossed,
the ratio of offspring was Mendelian with respect to the mutant ADAM12
allele (Table II). Genotyping was performed by Southern blot as described
previously (Weskamp et al., 2002; Horiuchi et al., 2003; Kurisaki et al.,
2003). All animals used in this work were of mixed genetic background
(129Sv/C57Bl6).
The histopathological analysis of adam9/15
 /  mice was performed as
described previously for adam9
 /  or adam15
 /  mice (Weskamp et al.,
2002; Horiuchi et al., 2003). Histopathological analysis of adam9/12/15
 / 
mice was performed by the Memorial Sloan-Kettering Cancer Center
mouse phenotyping core. No abnormalities or pathological phenotypes
were observed in adam9/15
 /  and adam9/12/15
 /  mice. Serial sections
of tissues affected in egfr
 / , hb-egf
 / , and tgf 
 /  mice did not uncover
any evident defects in adam9/12/15
 /  mice. Specifically, there were no
defects in the development of the heart or its valves (Fig. 3 B, panels E–P),
and also no defects in epithelia, intestine, lung, or in hair development. Fi-
nally, adam9/12
 /  double knockout and adam9/12/15
 /  triple knockout
mice were indistinguishable from wild-type controls in their appearance
and behavior during routine handling.
To generate adam9/12/15/17
 /  quadruple knockout mice, adam9/12/
15
 /  triple knockout mice were mated with adam17
 /  animals. Offspring
from this mating that were heterozygous for the targeted allele of all four
ADAMs were identified by Southern blotting, and were backcrossed sev-
eral times with adam9/12/15
 /  triple knockout mice to obtain adam9
 / 
12
 / 15
 / 17
 /  mice. Crosses of adam9
 / 12
 / 15
 / 17
 /  mice pro-
duced litters with a similar distribution of the targeted ADAM17 allele at
E18.5 to what has been reported from crosses of adam17
 /  mice (Table
III; Peschon et al., 1998). Histopathological evaluation of newborn adam9/
12/15/17
 /  quadruple knockout mice did not uncover any significant
worsening of the developmental defects described for adam17
 /  mice.
The cause for the slightly increased embryonic lethality of adam9/12/15/
17
 /  mice compared with adam17
 /  mice (Table III) remains to be deter-
mined. Images of fixed and hematoxylin and eosin–stained heart sections
mounted in Permount/Histoclear were acquired with Axiovision software
via an Axiocam HRC camera mounted on an Axioplan2 microscope (soft-
ware, camera, and microscope all from Carl Zeiss MicroImaging, Inc.). The
objective was a Plan-Neofluar 10 /0,30 (44 03 30; Carl Zeiss MicroImag-
ing, Inc.) lens. Images were processed with Adobe Photoshop
® 7.0, and
the surface area of heart valves in serial sections was measured using NIH
Image 1.63 software.
Expression vectors for AP-tagged EGFR ligands
Plasmids encoding AP-tagged EGFR ligands were constructed by inserting
partial cDNAs for human TGF , amphiregulin, epiregulin, EGF, betacellu-
lin, and HB-EGF into the 3  end of human placental AP cDNA on a pRc/
CMV-based expression vector pAlPh. pAlPh contains an NH2-terminally
located HB-EGF signal sequence. In all cases, the junction between AP
and the EGFR ligand was placed next to the membrane-proximal EGF re-
peat. Release of the AP module into the culture supernatant thus requires
cleavage at the COOH-terminal cleavage site. It should be noted that the
results obtained with AP-tagged EGFR ligands corroborate previous results
that TGF , HB-EGF, and amphiregulin are cleaved by ADAM17 (Peschon
et al., 1998; Merlos-Suarez et al., 2001; Sunnarborg et al., 2002; Jackson
et al., 2003). This validates the use of AP tags to measure ectodomain
shedding for these substrates. In addition, the use of an AP tag has been in-
dependently validated using the TNF family members TNF  and TRANCE/
OPGL (Zheng et al., 2002; Chesneau et al., 2003). This strongly suggests
that an AP tag, which provides a sensitive and quantitative means of mea-
suring ectodomain shedding, should not interfere with the shedding prop-
erties of the other EGFR ligands tested here.
Generation of primary MEFs
Primary MEFs were generated from wild-type or adam
 /  E13.5 embryos
and were cultured as described previously (Weskamp et al., 2002). In ad-778 The Journal of Cell Biology | Volume 164, Number 5, 2004
dition to adam9/12/15
 /  triple knockout and adam9/12/15/17
 /  qua-
druple knockout mice, we also used adam17
 /  (Peschon et al., 1998) and
adam19
 /  (Zhou et al., 2004) mice as well as wild-type controls of mixed
genetic background (129Sv/C57Bl6) to generate the corresponding pri-
mary mEF cells. All genotyping was performed by Southern blot analysis.
adam10
 /  fibroblast cell lines derived from E9.5 embryos have been de-
scribed previously (Hartmann et al., 2002).
Northern blot analyses
Procedures for isolation of mRNA, gel electrophoresis, transfer to mem-
branes, and generation of 
32P-labeled cDNA probes of the indicated
ADAMs under high stringency were described previously (Weskamp and
Blobel, 1994).
Transfections and shedding assays
cDNA constructs encoding AP-EGFR ligand fusion proteins were trans-
fected with LipofectAMINE™ (Invitrogen). Fresh Opti-MEM (Invitrogen)
medium was added the next day, incubated for 1 h, and then replaced
with fresh medium containing either 20 ng/ml PMA or 1  M batimastat
(provided by D. Becherer, GlaxoSmithKline, Research Triangle Park, NC),
which was also collected after 1 h. Evaluation of AP activity by SDS-PAGE
or by colorimetric assays was performed as described previously (Zheng et
al., 2002). No AP activity was present in conditioned media of nontrans-
fected cells.
Western blot analysis
Western blot analysis of the expression of ADAM10 and ADAM17 in MEFs
and in different mouse tissues was performed as described previously
(Weskamp et al., 1996). The blots were probed with a polyclonal antise-
rum against ADAM10 (CHEMICON International) and against ADAM17
(Schlöndorff et al., 2000).
Statistical analyses
t tests for two samples assuming equal variances were used to calculate the
P values. P values  0.05 were considered statistically significant.
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